{
  "report_rows": [
    {
      "kpi": "2Q26 Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$9.46B vs. cons $9.426B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2Q26 Operating Diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$5.66 vs. cons $5.584",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2Q26 Repatha revenue",
      "prediction": "BEAT",
      "answer": "pred ~$935M vs. cons $922M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 Revenue",
      "prediction": "UNCHANGED",
      "answer": "guide $37.1B-$38.5B vs. cons $37.817B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 Non-GAAP EPS",
      "prediction": "UNCHANGED",
      "answer": "guide $21.70-$23.10 vs. cons $22.36",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 Operating Margin / Denosumab Commentary",
      "prediction": "UNCHANGED",
      "answer": "guide ~45%-46%; denosumab erosion as planned vs. cons UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -1.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH - maintained FY guidance implies modestly softer out-period math",
  "day5_confidence": "LOW"
}